Showing results (71-80 of 93) with videos related to
Sort By:
Pageof 10
The Oncologist|January 25, 2021
Pembrolizumab in Patients with Advanced Metastatic Germ Cell TumorsApostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantationApostolia-Maria Tsimberidou, Susan O'Brien, Issa Khouri, et al.Journal of the National Cancer Institute|November 25, 2015
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine TrialsChristophe Le Tourneau, Maud Kamal, Apostolia-Maria Tsimberidou, et al.Molecular Cancer Therapeutics|December 17, 2010
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancerApostolia-Maria Tsimberidou, Wallace Akerley, Matthias C Schabel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.Journal of Hematology & Oncology|August 19, 2021
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancerApostolia-Maria Tsimberidou, Jamie V Shaw, Dejan Juric, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.The Oncologist|June 29, 2026
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid TumorsApostolia Maria Tsimberidou, Darren Sigal, Anna Varghese, et al.Pageof 10